ConductScience.org, home

Paper16815744

Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.

Roth T and 4 others. Sleep Med, 2006. Cited by 89 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Papers, record 16815744. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16815744

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
PubMed
Journal
Sleep Med
PubMed
Year
2006
PubMed
Publication types
Journal Article, Multicenter Study, Randomized Controlled Trial
PubMed
Citations, by iCite
89
iCite
Relative citation ratio, by iCite
3.08
iCite
Revised in PubMed
2018-12-01
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Roth TThomas
2Soubrane CChristina
3Titeux LLaurence
4Walsh JKJames K
5Zoladult Study GroupGroup

Source PubMed

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hypnotics and SedativesMajor topic
PyridinesMajor topic
Sleep Initiation and Maintenance DisordersMajor topic
Adolescent
Adult
Delayed-Action Preparations
Double-Blind Method
Female
Humans
Male
Middle Aged
Polysomnography
Psychomotor Performance
Sleep
Surveys and Questionnaires
Zolpidem

Source PubMed

Cited by42

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 89 citations.

PMIDTitleJournalYearIn PapersSource
41,957,444Insomnia disorder.Nat Rev Dis Primers2026https://conductscience.org/library/papers/41957444PubMed
41,005,810Impact of positive airway pressure for chronic hypercapnic respiratory failure on sleep quality: a systematic review and meta-analysis.Eur Respir Rev2025https://conductscience.org/library/papers/41005810PubMed
40,225,286Perception of Lemborexant Effectiveness as Assessed by the Patient Global Impression-Insomnia Questionnaire.Nat Sci Sleep2025https://conductscience.org/library/papers/40225286PubMed
38,748,321Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder.Neurol Ther2024https://conductscience.org/library/papers/38748321PubMed
38,370,8792023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association.Sleep Sci2023https://conductscience.org/library/papers/38370879PubMed
37,829,761Severe chronic abuse of zolpidem for over 10 years: a case report and review of similar cases.Front Psychiatry2023https://conductscience.org/library/papers/37829761PubMed
37,513,909Indol-3-ylglyoxylamide as Privileged Scaffold in Medicinal Chemistry.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37513909PubMed
36,947,394The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials.Drugs2023https://conductscience.org/library/papers/36947394PubMed
36,061,292
Case report: Chronological symptom profile after cessation of overdose zolpidem in a patient with comorbid bipolar disorder-from anxiety, craving, paresthesia and influenza-like symptoms to seizures and hallucinations.
Front Psychiatry2022https://conductscience.org/library/papers/36061292PubMed
35,749,758Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users.J Clin Psychopharmacol2022https://conductscience.org/library/papers/35749758PubMed
35,402,894Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder.Sleep Med X2022https://conductscience.org/library/papers/35402894PubMed
35,162,009External Auditory Stimulation as a Non-Pharmacological Sleep Aid.Sensors (Basel)2022https://conductscience.org/library/papers/35162009PubMed
34,708,126An Update on Assessment, Therapeutic Management, and Patents on Insomnia.Biomed Res Int2021https://conductscience.org/library/papers/34708126PubMed
34,121,443Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.J Manag Care Spec Pharm2021https://conductscience.org/library/papers/34121443PubMed
31,496,087The assessment and management of insomnia: an update.World Psychiatry2019https://conductscience.org/library/papers/31496087PubMed
30,144,651How representative are insomnia clinical trials?Sleep Med2018https://conductscience.org/library/papers/30144651PubMed
29,792,241Efficacy of digital CBT for insomnia to reduce depression across demographic groups: a randomized trial.Psychol Med2019https://conductscience.org/library/papers/29792241PubMed
27,998,379Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.J Clin Sleep Med2017https://conductscience.org/library/papers/27998379PubMed
27,397,664Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.J Clin Sleep Med2016https://conductscience.org/library/papers/27397664PubMed
26,609,210Pharmacological Treatment of Insomnia.P T2015https://conductscience.org/library/papers/26609210PubMed

See all 42 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/16815744

GET https://conductscience.org/api/papers/v1/16815744/cited_by?page=2